[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiogenic-shock-post-myocardial-infarction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiogenic-shock-post-myocardial-infarction":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,46,77,103,131,160,180],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641466","rapid-microaxial-flow-pump-support-and-escalation-in-patients-with-myocardial-infarction-associated-cardiogenic-shock-and-persistent-need-of-hemodynamic-support-100641466",false,"NCT07655479","Rapid Microaxial Flow Pump Support and Escalation in Patients With Myocardial Infarction Associated Cardiogenic Shock and Persistent Need of Hemodynamic Support","Rapid Impella Support and Escalation Trial","RISE","Inclusion Criteria:\n\n1. Age ≥18 years and ≤77 years\n2. Patients with ACS-CS (STEMI and NSTEMI with a culprit lesion that received revascularisation) and Impella CP™ support during initial revascularisation\n3. The following additional parameters must be met at the time of initial revascularisation procedure:\n\n   1. Hypotension or need for inotropes AND\n   2. Lactate \\> 2.5 mM AND\n   3. Left ventricular ejection fraction (EF) \\\u003C 45%\n4. Need for escalation to Impella 5.5 at the discretion of the treating physician and the following criteria are fulfilled:\n\n   1. Decision for Impella 5.5 escalation within 6 ± 1 hours after completion of initial revascularisation procedure\n   2. Escalation to Impella 5.5procedure is initiated within 24 hours after completion of the initial revascularisation procedure\n5. Need for inotropes and\u002For vasopressors with VIS \\> 5 but ≤ 50 at Impella CP™ support at level P7 or above at 6+1 hours after completion of initial revascularisation procedure\n6. Prospective Informed Consent obtained from the patient or deferred consent according to \"Cologne Model\" applied.\n\nExclusion Criteria:\n\n1. Implanted VA-ECMOwithin 6 ± 1 hours after initial revascularisation Note: If VA-ECMO support is needed between 6 ± 1 hours after initial revascularisation and escalation to Impella 5.5, patients will be included forlimited data collection per Table 2 only. In this case the same Informed Consent Process as for regular trial participants applies.\n2. Elevated risk of hypoxic brain injury indicated by MIRACLE2 score \\>3 (Aldous et al., 2023)\n3. Platelet count \\\u003C75,000 cells\u002Fmm3, bleeding diathesis or active bleeding, coagulopathy or unwillingness to receive blood transfusions\n4. Active bleeding (e.g. access site bleeding or GI bleeding, etc.) with need for transfusion within 6 ± 1 hours after initial revascularisation\n5. Any contraindication listed in the Impella 5.5 IFU if known to be present\n6. Chronic haemodialysis and\u002For chronic kidney disease stage G5 according to KDIGO\n7. Pregnancy or lactation, if known\n8. Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device that has not reached its primary endpoint, if known","ALL","18 Years","77 Years",{"count":21,"type":22},115,"ESTIMATED","6 Months","OBSERVATIONAL","The aim of this trial is to evaluate whether a structured and time-optimized escalation strategy from a transfemoral microaxial flow-pump (Impella CP™) to the Impella 5.5™ microaxial flow-pump is associated with improved clinical outcomes and fewer adverse events in patients with cardiogenic shock due to acute myocardial infarction",[27],"Cardiogenic Shock Post Myocardial Infarction",[29,30,31,32],"Impella","Microaxial Flow-pump","cardiogenic shock","myocardial infarction","RECRUITING","2026-06-19",{"date":36,"type":37},"2026-06-24","ACTUAL",{"date":39,"type":37},"2026-04-23",{"date":41,"type":22},"2028-10",{"name":43,"class":44},"University Hospital of Cologne","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100642943","cardiovascular-outcomes-registry-in-cardiogenic-shock-cor-shock-100642943","NCT07597291","Cardiovascular Outcomes Registry in Cardiogenic SHOCK (COR-SHOCK)","Cardiovascular Outcomes Registry in Cardiogenic SHOCK","COR-SHOCK","Inclusion Criteria:\n\n-Cardiogenic shock according to the following criteria:\n\nCardiac disorder resulting in hypotension, defined as at least one of the following:\n\n* Systolic blood pressure (SBP) \\\u003C90 mmHg for ≥30 minutes, or\n* Requirement for vasopressors, inotropes, or mechanical circulatory support to maintain SBP ≥90 mmHg\n\nAND\n\nEvidence of tissue hypoperfusion, defined by the presence of at least one of the following:\n\n* Serum lactate \\>2 mmol\u002FL\n* Acute kidney injury and\u002For oliguria\n* Acute hepatic injury\n* Cool or mottled extremities\n* Altered mental status\n\nAND\n\nClinical presentation judged to be primarily attributable to a cardiac etiology.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years.\n* Other primary etiologies of shock at presentation (e.g., hypovolemic, hemorrhagic, septic, obstructive shock due to acute pulmonary embolism, or anaphylactic shock).\n* Refusal to participate in the study (applicable only to the prospective cohort).",{"count":55,"type":22},800,"The goal of this observational study is to evaluate the clinical outcomes and management approaches of cardiogenic shock throughout the years in adult patients admitted to a Cardiology Department. The main questions it aims to answer are:\n\n* How have management strategies and clinical outcomes for cardiogenic shock evolved over time?\n* How do clinical, laboratory, and advanced hemodynamic monitoring parameters relate to patient survival and overall prognosis in this population?\n\nResearchers will evaluate clinical data collected from 2017 onwards to see if therapeutic advancements and changes in clinical management over the years have led to improved patient survival and quality of care.\n\nParticipants will:\n\n* Receive standard, routine medical care for cardiogenic shock as determined by their clinical team (no experimental interventions will be introduced).\n* Have their clinical, laboratory, and imaging data collected from hospital electronic records during their stay.\n* Be followed for up to 1 year after hospital admission to evaluate long-term survival and clinical outcomes.",[58,59,27],"Cardiogenic Shock Acute","Cardiogenic Shock",[59,61,62,63,64,65,66,67],"Shock, Cardiogenic","Hemodynamic Monitoring","Pulmonary Artery Catheterization","Swan-Ganz","Mechanical Circulatory Support","Prognosis","Myocardial Infarction","2026-06-09",{"date":70,"type":37},"2026-06-11",{"date":72,"type":37},"2026-06-10",{"date":74,"type":22},"2036-12-31",{"name":76,"class":44},"Hospital de Santa Cruz, Portugal",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":87,"conditions":88,"keywords":89,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":45},"100638835","optimize-55---optimizing-impella-55-outcomes-through-advanced-data-science-100638835","NCT07619144","OPTIMIZE 5.5 - Optimizing Impella 5.5 Outcomes Through Advanced Data Science","Clinical Outcomes and Adverse Events Associated With Microaxial Flow Pump Support: An Explorative Retrospective Study","OPTIMIZE","Inclusion Criteria:\n\n* Adult patients who were treated for cardiogenic shock and supported with an Impella 5.5 micro-axial flow pump\n* Only patients with available high-resolution pump data (downloaded from the clinical console) and ICU digital health record datasets\n\nExclusion Criteria:\n\n* Patients supported with an Impella 5.5 for indications other than cardiogenic shock (e.g., protected PCI or CABG)\n* Patients younger than 18 years\n* Patients with incomplete data, procedural records, or demographic information",{"count":86,"type":22},100,"The main goal of this observational, study is to develop a clinical decision support tool utilizing Impella 5.5 pump parameters to predict native heart recovery and prevent adverse events, by leveraging data science and real-world clinical data of cardiogenic shock patients.\n\nTherefore, secondary objectives are essential to consolidating a retrospective longitudinal analysis of Impella 5.5 pump data alongside ICU digital health record datasets to:\n\n1. Validate the Impella 5.5 placement signal by comparing it with ICU arterial line waveforms.\n2. Integrate pump data with ICU clinical data to identify patterns associated with therapy outcomes, including native heart recovery, heart replacement therapy, and mortality while on device support.\n3. Define clinical scenarios linked to hemolysis, HRAEs, and arrhythmias and develop predictive models to mitigate their occurrence.",[59,65,27],[31,90,91,92,93],"mechanical circulatory support","Impella 5.5","micro-axial flow pump","data science","2026-05-27",{"date":96,"type":37},"2026-06-01",{"date":98,"type":37},"2026-05-08",{"date":100,"type":22},"2029-05-30",{"name":102,"class":44},"Medical University of Vienna",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":114,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":45},"100622210","phase-1-safety-and-efficacy-of-fap-icdc-in-acute-myocardial-infarction-with-cardiogenic-shock-100622210","NCT07380659","Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock","Safety and Efficacy of Allogeneic Immunosuppressive CAR-DC Targeting FAP in the Treatment of Acute Myocardial Infarction With Cardiogenic Shock","Inclusion Criteria（patients）:\n\n* Age ≥ 18 years and \\\u003C 80 years.\n* Acute ST-segment elevation myocardial infarction (STEMI) complicated by cardiogenic shock, meeting all the following conditions:\n\n  1. Post-emergent revascularization (PCI or CABG)\n  2. Systolic blood pressure \\\u003C 90 mmHg for \\>30 minutes, or requiring catecholamine support to maintain systolic blood pressure \\>90 mmHg\n  3. Signs of impaired organ perfusion, meeting at least one of the following criteria:\n\n     1. Altered mental status\n     2. Cold, clammy skin and extremities\n     3. Oliguria, with urine output \\\u003C30 mL\u002Fh\n     4. Arterial lactate level \\>2 mmol\u002FL\n* The patient or their legally authorized representative is capable of providing verbal confirmation of understanding the trial risks, benefits, and treatment alternatives associated with receiving immunosuppressive CAR-DC therapy, and provides written informed consent prior to participation in this clinical trial.\n\nExclusion Criteria（patients）:\n\n1. Acute mechanical complications of infarction (e.g., ventricular septal rupture, acute mitral regurgitation).\n2. Cardiac arrest.\n3. Hypoxic-ischemic brain injury (cerebral injury with fixed and dilated pupils not attributable to medication).\n4. Shock due to other causes (e.g., sepsis, hypovolemia).\n5. Resuscitation duration \\>30 minutes.\n6. Absence of spontaneous cardiac activity.\n7. Persistent electrical instability.\n8. Active bleeding or contraindications to heparin use.\n9. Active autoimmune disease requiring immunosuppressive therapy.\n10. History of malignancy.\n11. Infection, including:\n\n    * Active hepatitis B (HBV DNA \\>1000 copies\u002FmL by PCR), hepatitis C, syphilis, or HIV infection at screening.\n    * Uncontrolled systemic fungal, bacterial, viral, or other pathogen infections.\n12. Pregnant women.\n13. Contraindications to the investigational drug or study procedures.\n\nInclusion Criteria（donors）:\n\n* Age ≥ 18 years and ≤ 75 years.\n* Has provided written informed consent.\n* Hematocrit \\>30%, lymphocyte count \\>0.5 × 10\\^9\u002FL, platelet count \\>60 × 10\\^9\u002FL.\n* Pathogen screening results must be negative for HIV (antigen, core antibody, and RNA), HBV (surface antigen and core antibody), HCV, syphilis, CMV, and EBV.\n\nExclusion Criteria（donors）:\n\n* Active infection requiring treatment.\n* History of malignancy.\n* Active autoimmune disease requiring immunosuppressive therapy.","80 Years",{"count":112,"type":22},18,"INTERVENTIONAL",[115],"PHASE1","To study the safety and efficacy of fibroblast activation protein (FAP)-targeted allogeneic immunosuppressive chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of acute myocardial infarction with cardiogenic shock and provide a new method for the treatment of acute myocardial infarction with cardiogenic shock.",[59,27,118],"STEMI - ST Elevation Myocardial Infarction",[120],"acute myocardial infarction with cardiogenic shock","NOT_YET_RECRUITING","2026-01-28",{"date":124,"type":37},"2026-02-02",{"date":126,"type":22},"2026-01-20",{"date":128,"type":22},"2027-02-28",{"name":130,"class":44},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":45},"100620203","prognosis-of-patients-with-mixed-cardiogenic-vasoplegic-shock-100620203","NCT07354568","Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock","Prognosis of Patients With Mixed Cardiogenic-Vasoplegic Shock: a French Multicenter Cohort","PROMIX","Inclusion Criteria:\n\n* Adult patient (\\>18 years old)\n* Admitted to an intensive care unit for cardiogenic shock, at least SCAI stage C\n* No opposition to data use\n\nExclusion Criteria:\n\n* Missing key data, particularly regarding vasopressor doses and outcomes.\n* Pregnant women\n* Non-eligible shock etiologies, including but not limited to:\n* Anaphylactic shock,\n* Isolated hemorrhagic shock,\n* Severe burns or major trauma,\n* Severe acute pancreatitis,\n* Fulminant hepatic failure,\n* Neurogenic shock.\n* Adult under legal protection (guardianship, curatorship, or judicial protection).",{"count":140,"type":22},2500,"Mixed cardiogenic-vasoplegic shock (M-CS) represents a distinct and severe phenotype of cardiogenic shock characterized by concomitant myocardial dysfunction and inappropriate systemic vasodilation. Despite its clinical relevance, the epidemiology, management, and outcomes of M-CS remain poorly defined.\n\nThis retrospective, multicenter, observational registry aims to evaluate the clinical outcomes and prognostic factors associated with mixed cardiogenic-vasoplegic shock. The study will analyze clinical, biological, and invasive hemodynamic data routinely collected during patient management for M-CS.\n\nAll included patients will have been admitted for cardiogenic shock, with or without vasoplegia, defined by low cardiac output and, when present, decreased systemic vascular resistance despite adequate filling pressures requiring vasopressor support.\n\nThe primary objective is to describe mortality and organ failure rates, while secondary analyses will identify determinants of adverse outcomes and potential phenotypic subgroups.\n\nThe PROMIX registry will be conducted across three French university hospitals (CHU Amiens-Picardie, CHU Dijon-Bourgogne, and CHU Rouen-Normandie).\n\nThis study is non-interventional, involving only data obtained as part of routine critical care, and will provide the first multicenter overview of this complex and underrecognized form of cardiogenic shock.",[58,143,144,65,145,27],"Bypass, Cardiopulmonary","Septic Shock","Myocardial Infarction (MI)",[147,59,65,148,149,150],"VA-ECMO","Vasopressor","Mixed Cardiogenic Shock","post cardiotomy shock","2026-01-15",{"date":153,"type":37},"2026-01-21",{"date":155,"type":37},"2025-10-20",{"date":157,"type":22},"2027-06-01",{"name":159,"class":44},"Centre Hospitalier Universitaire, Amiens",{"id":161,"slug":162,"hasResults":11,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":169,"conditions":170,"keywords":4,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":45},"100617793","hong-kong-cardiogenic-shock-initiative-100617793","NCT07323238","Hong Kong Cardiogenic Shock Initiative","HK CSI","Inclusion Criteria:\n\n* Diagnosis of acute myocardial infarction (AMI) with the ECG and\u002For biomarker evidence of S-T elevation myocardial infarction (STEMI) or non -S-T elevation myocardial infarction (NSTEMI)\n* Cardiogenic Shock is defined as presence of at least two of the following\n\n  1. Hypotension (systolic blood pressure ≤ 100 mmHg, or inotropes\u002Fvasopressors to maintain systolic blood pressure ≥ 100 mmHg)\n  2. Evidence of end organ perfusion: elevated serum lactate levels (venous or arterial), cool extremities, oliguria\u002Fanuria\n  3. Hemodynamic criteria represented by cardiac index of \\\u003C2.2 L\u002Fmin\u002Fm² or a cardiac ≤ 0.6 watts\n* Patient is supported with a transvalvular MCS as the initial device (criteria for GCSI-eligible Cohort)\n* Patients undergo PCI within 12 hours of hospital presentation (criteria for GCSI-eligible Cohort)\n* Subject or legally designated representative (LDR) has provided written informed consent. For patients not able to provide consent, data collection will be conducted in retrospective manner with study consent waived.\n\nExclusion Criteria:\n\n* Unwitnessed out of hospital cardiac arrest or any cardiac arrest in which return of spontaneous circulation (ROSC) is not achieved within 20 minutes\n* Patients demonstrate any signs of anoxic brain injury prior to the INDEX PCI (signs of anoxic injury include, posturing, seizures).\n* IABP placed prior to MCS (criteria for GCSI-eligible Cohort)\n* Septic, anaphylactic, hemorrhagic, and neurologic causes of shock\n* Non-ischemic causes of shock\u002Fhypotension (pulmonary embolism, pneumothorax, myocarditis, tamponade, etc.)\n* Active bleeding for which MCS in contraindicated\n* Recent major surgery for which MCS is contraindicated\n* Mechanical complication of AMI (acute ventricular septal defect (VSD) or acute papillary muscle rupture)\n* Known left ventricular thrombus for which MCS in contraindicated (criteria for GCSI-eligible Cohort)\n* Mechanical aortic prosthetic valve (criteria for GCSI-eligible Cohort)\n* Contraindication to intravenous systemic anticoagulation which precludes placement of MCS.\n\nPatients who fulfills all Eligibility Criteria would be recruited and considered GSCI-eligible. AMI-CS patients that did not use MCS, ie. Not fulfiliing both Inclusion Criteria 3, 4, would not be considered screen failure and would still be screened and recruited into HKCSI GCSI-ineligible cohort. Likewise, patients who meet any of Exclusion Criteria will not be GCSI-eligible. Specifically, patients who met exclusion criteria 3, 9, 10 only will be recruited into GCSI-ineligible cohort.",{"count":168,"type":22},320,"Acute myocardial infarction complicated by cardiogenic shock (AMI-CS) is a severe condition with high mortality. Early revascularization and Impella device (Abiomed) support improve outcomes. Observational studies like the National Cardiogenic Shock Initiative (NCSI), Inova-Shock registry, and J-PVAD (Japan registry for percutaneous ventricular assist device) registry emphasize the importance of structured care systems when using mechanical circulatory support (MCS).\n\nFollowing the release of the Danger Shock trial, MCS use is expected to rise. Hospitals will need to monitor practices and work with payers to ensure coverage. Using regional real-world data can assist this process, making the collection and analysis of MCS outcomes essential.\n\nThe NCSI (NCT03677180) aimed to evaluate outcomes with a protocolized approach prioritizing rapid diagnosis, timely MCS delivery, and invasive hemodynamic monitoring via pulmonary artery (PA) catheters. The study involved 406 patients from 2016 to 2020, with an average age of 64 years. Most (67%) had shock, with 85% on vasoactive drugs. Witnessed outof-hospital cardiac arrest occurred in 17%, and in-hospital arrest in 30%. During MCS implantation, 9% were actively resuscitating. Patients mostly in SCAI stage C\u002FD (73%) and stage E (27%) presented with low blood pressure, high lactate, and reduced cardiac power output. About 70% received MCS before PCI, with 90% using PA catheters. Most had STEMI, with median door-to-support and door-to-balloon times of about 78 and 81 minutes. Survival rates were high: 99% procedural, 79% to discharge, 77% at 30 days, and 62% at one year for stage C\u002FD shock. Patients with stage E shock had lower survival. Early use of MCS improved hemodynamics and survival. Further research, like the CERAMICS (Can Escalation Reduce Acute Myocardial Infarction in Cardiogenic Shock) study, aims to refine escalation strategies. The Danger Shock trial highlighted the importance of minimizing complications such as bleeding, limb ischemia, haemolysis, and kidney injury.\n\nCurrently in Hong Kong, prevalence of CS among AMI patients is 5-10%, in-line with global statistics. Among which, 30-day and 1-year mortality of AMI-CS patients in Hong Kong was reported at 29% and 39.5% respectively. Although the use of MCS has been shown in the above overseas studies to improved survival rates of AMI-CS patients, the utilisation rate of MCS among AMI-CS patients in Hong Kong was reported at 36.5% in a previous single-centre study, limited by an array of factors including limited device availability, allocations of resources and patient selection strategy, lack of region-specific evidence and device affordability. Global Cardiogenic Shock Initiative (GCSI) is an ongoing international multicenter registry involving centers from USA, Germany, and Hong Kong, and focus on the outcomes of AMI-CS patients received Impella support. The GCSI is expanding to many other regions. In the Hong Kong Cardiogenic Shock Initiative (HK-CGSI) study we aim to include sites with experience in MCS, all of whom have the capability of MCS escalation and evaluate outcomes across these centers.\n\nThe goal is not only to capture the effects of previously established best practices but gain insights into regional best practices, and together with data from the global cardiogenic shock initiative (GCSI), to better establish the adoption of novel best practices and their effect on complication rates.\n\nIn parallel to GCSI-eligible cohort, i.e. Impella used as the first supporting device for patients with AMI-CS, given the significant portion of patients who could not receive MCS under current limitations in Hong Kong, in the HK-CSI, we will include also the GCSI-ineligible cohort, i.e. AMI-CSI without using Impella or not as the first MCS used, to understand the full picture of clinical outcomes of AMI-CS patients of Hong Kong.\n\nThe HK-CSI study is an observational registry solely and not a treatment study. This single-arm registry captures data generated during procedures which are considered standard of care. Participation in this registry will be performed with waiver of consent of the patient and will have no influence on the type and extent of treatment.",[58,118,59,27,65],"2026-01-07",{"date":173,"type":37},"2026-01-09",{"date":175,"type":22},"2026-04-01",{"date":177,"type":22},"2030-10-02",{"name":179,"class":44},"Prince of Wales Hospital, Shatin, Hong Kong",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":187,"targetDuration":4,"studyType":113,"phases":189,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":45},"100590421","early-beta-blocker-administration-in-stemi-patients-with-scai-b-status-100590421","NCT06967194","Early Beta Blocker Administration in STEMI Patients With SCAI B Status","Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status","Inclusion Criteria:\n\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.\n* Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and\u002For hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \\>0.5 mL\u002Fkg\u002Fhour).\n* Age 18 years or older.\n* Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Inability to provide informed consent.\n* Evidence of pulmonary edema.\n* Bradycardia (heart rate \\\u003C60 beats per minute).\n* PR interval \\>240 milliseconds.\n* Second- or third-degree atrioventricular (AV) block.\n* Active asthma.\n* Known hypersensitivity to metoprolol.",{"count":188,"type":22},200,[190],"NA","This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.\n\nWhen patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.\n\nDuring the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.\n\nThe main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.",[193,27],"ST Segment Elevation Myocardial Infarction (STEMI)",[195,196,197],"acute MI","stemi","beta blockers","2025-05-21",{"date":200,"type":37},"2025-05-28",{"date":198,"type":37},{"date":203,"type":22},"2027-06",{"name":205,"class":206},"Tel-Aviv Sourasky Medical Center","OTHER_GOV"]